
Why I Plan To Buy This Fast Growing Recession-Proof Blue-Chip
Posted On February 14, 2019 9:40 am
By: Dividend Sensei
By: Dividend Sensei
Today this fast-growing blue-chip offers 11% to 12% return potential, but at the right price much more. Find out why I plan to buy it, but more importantly at what price it’s likely to turn into an even better market smashing success.
Summary
- My Deep Value Dividend Growth Portfolio is always looking for the best low-risk dividend growth ideas, including those in recession-proof industries.
- The pharma industry is a solid defensive source of stable and growing income, BUT due to its high risk profile, I only recommend dividend blue-chips.
- Merck is one of my favorite drug makers due to its blockbuster oncology drugs like Keytruda, with more on the way due to a strong drug pipeline.
- Unfortunately, Merck is about 5% to 8% overvalued and thus new investors should wait to buy at $71 to $75 (I’m waiting for $67).
- From today’s price, Merck is likely to deliver about 11% to 12% long-term total returns, but I’m personally looking for 13% and thus have it watchlisted.
Photo: “Buy Key” by Got Credit is licensed under CC BY
Leave a reply